Based on the progression-free survival results from the IMpassion130 trial for people with metastatic triple-negative breast cancer whose tumours expressed PD-L1 (≥1%), in 2019 the FDA granted accelerated approval for the combination of atezolizumab and nab-paclitaxel as frontline treatment of PD-L1+ mTNBC. Here, CD274 is linked to neoplasm.